Cell Viability Assays Market Size, Share, and Industry Analysis, By Product (Equipment and Reagents & Kits), By Application (Stem Cell Research, Diagnosis, and Drug Discovery & Development), By End-Users (Hospitals & Clinics, Clinical Laboratories, Academic & Research Centers, and Others), and Region Forecast, 2026-2034

The global cell viability assays market size was valued at USD 4.99 billion in 2025. The market is projected to grow from USD 5.46 billion in 2026 to USD 11.29 billion by 2034, exhibiting a CAGR of 9.50% during the forecast period. A cell viability assay is carried out to assess cells' physical and physiological status when subjected to extracellular stimuli, treatments, and some chemical agents. These assays are applicable for determining optimal growth conditions in a particular cell culture.

Measurement of cell viability is essential for developing new drug therapies for chronic diseases such as cancer. The key factor driving the market expansion for cell viability assays is the rising number of people with chronic conditions.

• For instance, according to data published by WHO in February 2022, nearly 10 million people died due to cancer in 2020, making it the leading cause of death globally. The most common cancers are breast, prostate, lung, colon, and rectum cancer.

Furthermore, government and non-government entities are heavily investing in developing therapeutics for cancer, which is expected to fuel the growth in the market.

• For instance, in February 2022, according to data published by National Cancer Institute, President Biden announced a re-ignition of the cancer moonshot. He highlighted new goals: to reduce the death rate caused by cancer within 25 years and improve cancer patients' quality of life.

Impact of COVID-19 on the Cell Viability Assays Market

The cell viability assay market faced a slightly positive impact in 2020 due to the initiation of drug discovery and treatment programs related to cell viability assay. Cellular-based therapies have considerably increased the usage of the cell viability assay during the COVID-19 pandemic to comprehend the viability and response of living cells to COVID-19 infection.

For instance, in August 2020, Calidi Biotherapeutics announced FDA Approval for the IND (investigational new drug) application submitted for COVID-19 treatment. This application was submitted by its partner, Personalized Stem Cells (PSC), a biopharmaceutical company. Calidi Biotherapeutics has partnered with PSC for two years to contribute to stem cell therapy manufacturing for COVID-19 patients.

Stem cell therapy has received the greatest attention as a new treatment method, and research method for COVID-19, and stem cells are playing an important role in fighting against COVID-19. More cell viability assays were performed due to the growing need for stem cell therapy; hence the market is anticipated to expand in the coming years. Additionally, increasing R&D will allow market players to introduce new products anticipated to accelerate market expansion.

• For instance, in January 2022, according to data published in Springer, stem cell therapy is available only for patients who have recovered from severe COVID-19 complications to repair damaged lungs, making it an ideal treatment.

Key Insights

The following key insights will be covered in the report:

• Prevalence of Key Chronic Diseases - by Key Countries/Regions, 2022.
• New Product Launches, Key Players.
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.).
• Impact of COVID-19 on the Cell Viability Assays Market.

Analysis by Products

Based on the product, the instruments segment accounted for a considerable proportion of the cell viability assay market in 2022. The growth was mainly attributed to the constant innovation and the development of new staining methods for delivering appropriate results.  

• For instance, in November 2022, as per the article published by Springer Nature Limited, imaging flow cytometry combines the high-event-rate nature of flow cytometry with the advantages of single-cell image acquisition associated with microscopy. 
• In November 2021, as per the article published by Select Science, flow cytometry enhanced the accuracy and limits the non-specific staining by using new tools.
• In March 2019, according to data published on B.D., the new automated flow cytometry sample preparation instrument was launched by B.D. having CE-IVD certification

Regional Analysis

Request for Customization   to gain extensive market insights.

North America dominated the cell viability assay market in 2022 and is projected to maintain its position over the forecast period. The majority of the growth in the U. S. is due to the rising cancer burden and steadily growing geriatric population. The key reasons fueling the market growth are the rising prevalence of cancer, an established medical infrastructure, and advanced diagnostic testing. The increasing population burden due to cancer is a key factor driving the market growth.

• For instance, according to data published by the American Cancer Society, Inc., cancer is Canada's primary cause of death. Prostate cancer in males and breast cancer in females are the most commonly diagnosed type of cancer, while lung cancer remains the most common cause of cancer death in both sexes. It was estimated that around 1.9 million new cancer cases and 693,000 cancer deaths occurred in Northern America in 2018.  

Key Players Covered

The profile of key players will be included in the reports, such as Thermo Fisher Scientific Inc., Abcam plc., PerkinElmer Inc., Merck KGaA, Bio-Rad Laboratories Inc., Promega Corporation., Agilent Technologies, Inc., Creative Bioarray, and others.

Segmentation

Key Industry Developments

• September 2022: Nanolive launched the live cell death assay. The company developed a ground-breaking tool that provides an automated solution for profiling cell health, death, apoptosis, and necrosis.
• October 2021: Curi Bio and NEXEL announced Celogics, a joint venture company, to develop leading iPSC-derived cell products. This partnership focused on developing and commercializing human iPSC-derived cell products for drug safety testing, drug discovery, and biological research.
• April 2021: Halo Labs launched the "Aura CL" for cell therapy. The product developed by the company can distinguish therapeutic cells from contaminants and other particles that might adversely harm patients. This product has been completely effective for cell therapy and product quality analysis. This product launch strengthens the company's scientific instrument product portfolio cell.